Heat Shock Proteins and Scavenger Receptors: Role in Adaptive Immune Responses

2005 ◽  
Vol 34 (3) ◽  
pp. 325-342 ◽  
Author(s):  
John G. Facciponte ◽  
Ian J. MacDonald ◽  
Xiang-Yang Wang ◽  
Hyung Kim ◽  
Masoud H. Manjili ◽  
...  
Keyword(s):  
Heat Shock ◽  
Heat Shock Proteins ◽  
Immune Responses ◽  
Scavenger Receptors ◽  
Adaptive Immune Responses ◽  
Adaptive Immune ◽  
Shock Proteins

scholarly journals Immune responses of leishmaniasis patients to heat shock proteins of Leishmania species and humans.

1995 ◽  
Vol 63 (10) ◽  
pp. 4105-4114 ◽  
Author(s):  
Y A Skeiky ◽  
D R Benson ◽  
J A Guderian ◽  
J A Whittle ◽  
O Bacelar ◽  
...  
Keyword(s):  
Heat Shock ◽  
Heat Shock Proteins ◽  
Immune Responses ◽  
Leishmania Species ◽  
Shock Proteins

scholarly journals A Mage3/Heat Shock Protein70 DNA vaccine induces both innate and adaptive immune responses for the antitumor activity

Vaccine ◽  
2009 ◽  
Vol 28 (2) ◽  
pp. 561-570 ◽  
Author(s):  
Lifeng Wang ◽  
Lisa Rollins ◽  
Qinlong Gu ◽  
Si-Yi Chen ◽  
Xue F. Huang
Keyword(s):  
Heat Shock ◽  
Antitumor Activity ◽  
Immune Responses ◽  
Dna Vaccine ◽  
Adaptive Immune Responses ◽  
Adaptive Immune

scholarly journals Myeloma cell line–derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma

Blood ◽  
2009 ◽  
Vol 114 (18) ◽  
pp. 3880-3889 ◽  
Author(s):  
Jianfei Qian ◽  
Sungyoul Hong ◽  
Siqing Wang ◽  
Liang Zhang ◽  
Luhong Sun ◽  
...  
Keyword(s):  
Heat Shock ◽  
Heat Shock Proteins ◽  
Immune Responses ◽  
Cell Line ◽  
Cell Lines ◽  
Tumor Antigens ◽  
Myeloma Cell ◽  
Myeloma Cell Line ◽  
Custom Made ◽  
Shock Proteins

Abstract Tumor cell–derived heat shock proteins are used as vaccines for immunotherapy of cancer patients. However, current approaches require the generation of custom-made products and are clinically ineffective. To improve the applicability of heat shock protein–based immunotherapy in cancers and to enhance clinical efficacy, we explored combinational treatments in a myeloma setting using pooled heterogeneous or allogeneic myeloma cell line–derived glycoprotein 96 (gp96) as universal vaccines, and clearly demonstrated that pooled but not single gp96 from heterogeneous or allogeneic myeloma cell lines was as effective as autologous gp96 in protecting mice from tumor challenge and rechallenge and in treating established myeloma. We showed that interferon γ and CD4+ and CD8+ T cells were required for gp96-induced antimyeloma responses and that pooled gp96 induced broader immune responses that protected mice from developing different myeloma. Furthermore, pooled gp96 plus CpG in combination with anti-B7H1 or anti–interleukin-10 monoclonal antibodies were effective in treating mice with large tumor burdens. Thus, this study strongly suggests that pooled gp96 vaccines from myeloma cell lines can replace gp96 vaccines from autologous tumors for immunotherapy and induce immune responses against broader tumor antigens that may protect against tumor recurrence and development of unrelated tumors in vaccinated myeloma patients.

Scavenger receptors and heat-shock protein-mediated antigen cross-presentation

2004 ◽  
Vol 32 (4) ◽  
pp. 633-635 ◽  
Author(s):  
Y. Delneste
Keyword(s):  
Monoclonal Antibody ◽  
Heat Shock ◽  
Immune Responses ◽  
Scavenger Receptors ◽  
Cross Presentation ◽  
Tumour Antigens ◽  
Shock Proteins ◽  
Human Hsp70

Heat-shock proteins (HSPs) induce protective cytotoxic immune responses against tumour antigens. This property is related to their ability to bind to and to be internalized by DC (dendritic cells) before gaining access to the MHC class I processing pathway, a process called antigen cross-presentation. This process requires internalization of the antigen by DC via endocytic receptors. Owing to their particular immune properties, several studies were focused on the identification of HSP-binding elements on DC. We and others have reported that scavenger receptors are the main HSP-binding structures on human DC and have identified LOX-1 as one of these molecules. The binding of human Hsp70 to DC and the in vitro Hsp70-mediated antigen cross-presentation are inhibited by an anti-LOX-1 monoclonal antibody. In vivo, targeting LOX-1 with a tumour antigen using an anti-LOX-1 monoclonal antibody induces antitumour immunity. Thus scavenger receptors are certainly new promising targets for cancer immunotherapy.

Sign in / Sign up

Export Citation Format

Share Document